News|Videos|November 6, 2023
Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
2
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
3
Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC
4
Dr Liu on Building on the ADRIATIC Regimen in Limited-Stage Small Cell Lung Cancer
5